πŸ‡ΊπŸ‡Έ FDA
Patent

US 10639375

Progesterone formulations

granted A61KA61K31/565A61K31/566

Quick answer

US patent 10639375 (Progesterone formulations) held by Compass Therapeutics LLC expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Compass Therapeutics LLC
Grant date
Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/565, A61K31/566, A61K31/57, A61K31/573